Profile of Substance Misuse among Adolescent and Young Adult Gabapentinoid Users: A Register-Based Follow-up Study of Former Adolescent Psychiatric Inpatients

References

• Alblooshi, H., Hulse, G. K., El Kashef, A., Al Hashmi, H., Shawky, M., Al Ghaferi, H., Al Safar, H., & Tay, G. K. (2016). The pattern of substance use disorder in the United Arab Emirates in 2015: Results of a National Rehabilitation Centre cohort study. Substance Abuse Treatment, Prevention, and Policy, 11, 19. https://doi.org/10.1186/s13011-016-0062-5
   PubMed Web of Science ®Google Scholar
• Ambrosini, P. J. (2000). Historical development and present status of the schedule for affective disorders and schizophrenia for school-age children (K-SADS). Journal of the American Academy of Child and Adolescent Psychiatry, 39(1), 49–58. https://doi.org/10.1097/00004583-200001000-00016
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders. Text revision (DSM-IV-TR). 4th ed. American Psychiatric Association.
   Google Scholar
• Anantharamu, T., & Govind, M. A. (2018). Managing chronic pain: Are gabapentinoids being misused? Pain Management, 8(5), 309–311. https://doi.org/10.2217/pmt-2018-0018
   PubMed Web of Science ®Google Scholar
• Bastiaens, L., Galus, J., & Mazur, C. (2016). Abuse of gabapentin is associated with opioid addiction. Psychiatric Quarterly, 87(4), 763–767. https://doi.org/10.1007/s11126-016-9421-7
   PubMed Web of Science ®Google Scholar
• Bockbrader, H. N., Wesche, D., Miller, R., Chapel, S., Janiczek, N., & Burger, P. (2010). A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clinical Pharmacokinetics, 49(10), 661–669. https://doi.org/10.2165/11536200-000000000-00000
   PubMed Web of Science ®Google Scholar
• Bodén, R., Wettermark, B., Brandt, L., & Kieler, H. (2014). Factors associated with pregabalin dispensing at higher than the approved maximum dose. European Journal of Clinical Pharmacology, 70(2), 197–204. https://doi.org/10.1007/s00228-013-1594-5
   PubMed Web of Science ®Google Scholar
• Bonnet, U., & Scherbaum, N. (2017). How addictive are gabapentin and pregabalin? A systematic review. European Neuropsychopharmacology, 27(12), 1185–1215. https://doi.org/10.1016/j.euroneuro.2017.08.430
   PubMed Web of Science ®Google Scholar
• Care Register for Health Care. (2020). Retrieved November 8, 2020, from https://thl.fi/en/web/thlfi-en/statistics/information-on-statistics/register-descriptions/care-register-for-health-care
   Google Scholar
• Chiappini, S., & Schifano, F. (2016). A decade of gabapentinoid misuse: An analysis of the European Medicines Agency’s ‘suspected adverse drug reactions’ database. CNS Drugs, 30(7), 647–654. https://doi.org/10.1007/s40263-016-0359-y
   PubMed Web of Science ®Google Scholar
• Daly, C., Griffin, E., Ashcroft, D. M., Webb, R. T., Perry, I. J., & Arensman, E. (2018). Intentional drug overdose involving pregabalin and gabapentin: Findings from the National Self-Harm Registry Ireland, 2007–2015. Clinical Drug Investigation, 38(4), 373–380. https://doi.org/10.1007/s40261-017-0616-y
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. (2020). Retrieved November 8, 2020, from https://www.ema.europa.eu/en/medicines/human/EPAR/lyrica
   Google Scholar
• Evoy, K. E., Morrison, M. D., & Saklad, S. R. (2017). Abuse and misuse of pregabalin and gabapentin. Drugs, 77(4), 403–426. https://doi.org/10.1007/s40265-017-0700-x
   PubMed Web of Science ®Google Scholar
• Finnish Medicines Agency (Fimea). (2016). Drug consumption in 2016. Retrieved November 8, 2020, from https://www.fimea.fi/web/en/databases_and_registeries/consumption
   Google Scholar
• Gahr, M., Freudenmann, R. W., Hiemke, C., Kölle, M. A., & Schönfeldt-Lecuona, C. (2013). Pregabalin abuse and dependence in Germany: Results from a database query. European Journal of Clinical Pharmacology, 69(6), 1335–1342. https://doi.org/10.1007/s00228-012-1464-6
   PubMed Web of Science ®Google Scholar
• Gomes, T., Juurlink, D. N., Antoniou, T., Mamdani, M. M., Paterson, J. M., & van den Brink, W. (2017). Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study. PLOS Medicine, 14(10), e1002396. https://doi.org/10.1371/journal.pmed.1002396
   PubMed Web of Science ®Google Scholar
• Goodman, C. W., & Brett, A. S. (2019). A clinical overview of off-label use of gabapentinoid drugs. JAMA Internal Medicine, 179(5), 695–701. https://doi.org/10.1001/jamainternmed.2019.0086
   PubMed Web of Science ®Google Scholar
• Hägg, S., Jönsson, A. K., & Ahlner, J. (2020). Current evidence on abuse and misuse of gabapentinoids. Drug Safety, 43(12), 1235–1254. https://doi.org/10.1007/s40264-020-00985-6
   PubMed Web of Science ®Google Scholar
• Häkkinen, M., Vuori, E., Kalso, E., Gergov, M., & Ojanperä, I. (2014). Profiles of pregabalin and gabapentin abuse by postmortem toxicology. Forensic Science International, 241, 1–6. https://doi.org/10.1016/j.forsciint.2014.04.028
   PubMed Web of Science ®Google Scholar
• Kaufman, J., Birmaher, B., Brent, D., Rao, U., Flynn, C., Moreci, P., Williamson, D., & Ryan, N. (1997). Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): Initial reliability and validity data. Journal of the American Academy of Child and Adolescent Psychiatry, 36(7), 980–988. https://doi.org/10.1097/00004583-199707000-00021
   PubMed Web of Science ®Google Scholar
• Kokkevi, A., & Hartgers, C. (1995). EuropASI: European adaption of a multidimensional assessment instrument for drug and alcohol dependents. European Addiction Research, 1(4), 208–210. https://doi.org/10.1159/000259089
   Google Scholar
• Markowitz, J. S., Finkenbine, R., Myrick, H., King, L., & Carson, W. H. (1997). Gabapentin abuse in a cocaine user: Implications for treatment?Journal of Clinical Psychopharmacology, 17(5), 423–424. https://doi.org/10.1097/00004714-199710000-00012
   PubMed Web of Science ®Google Scholar
• McNamara, S., Stokes, S., Kilduff, R., & Shine, A. (2015). Pregabalin abuse amongst opioid substitution treatment patients. Irish Medical Journal, 108(10), 309–310.
   PubMedGoogle Scholar
• Miettunen, J., Suvisaari, J., Haukka, J., & Isohanni, M. (2011). Use of register data for psychiatric epidemiology in the Nordic countries: Textbook of psychiatric epidemiology. In M. Tsuang, M. Tohen, and P. Jones (Eds.), Textbook of psychiatric epidemiology. Wiley-Balckwell.
   Google Scholar
• Molero, Y., Larsson, H., D’Onofrio, B. M., Sharp, D. J., & Fazel, S. (2019). Associations between gabapentinoids and suicidal behaviour, unintentional overdoses, injuries, road traffic incidents, and violent crime: Population based cohort study in Sweden. BMJ (Clinical Research ed.), 365, l2147. https://doi.org/10.1136/bmj.l2147
   PubMedGoogle Scholar
• Peckham, A. M., Fairman, K. A., & Sclar, D. A. (2017). Prevalence of gabapentin abuse: Comparison with agents with known abuse potential in a commercially insured US population. Clin Drug Investig, 37(8), 763–773. https://doi.org/10.1007/s40261-017-0530-3
   PubMed Web of Science ®Google Scholar
• Peckham, A. M., Fairma, K. A., & Sclar, D. A. (2018). All-cause and drug-related medical events associated with overuse of gabapentin and/or opioid medications: A retrospective cohort analysis of a commercially insured US population. Drug Safety, 41(2), 213–228. https://doi.org/10.1007/s40264-017-0595-1
   PubMed Web of Science ®Google Scholar
• Prokhorov, A. V., De Moor, C., Pallonen, U. E., Hudmon, K. S., Koehly, L., & Hu, S. (2000). Validation of the modified Fagerström tolerance questionnaire with salivary cotinine among adolescents. Addictive Behaviors, 25(3), 429–433. https://doi.org/10.1016/S0306-4603(98)00132-4
   PubMed Web of Science ®Google Scholar
• Prokhorov, A. V., Khalil, G. E., Foster, D. W., Marani, S. K., Guindani, M., Espada, J. P., Gonzálvez, M. T., Idrisov, B., Galimov, A., Arora, M., Tewari, A., Isralowitz, R., Lapvongwatana, P., Chansatitporn, N., Chen, X., Zheng, H., & Sussman, S. (2017). Testing the nicotine dependence measure mFTQ for adolescent smokers: A multinational investigation. The American Journal on Addictions, 26(7), 689–696. https://doi.org/10.1111/ajad.12583
   PubMed Web of Science ®Google Scholar
• Reccoppa, L., Malcolm, R., & Ware, M. (2004). Gabapentin abuse in inmates with prior history of cocaine dependence. The American Journal on Addictions, 13(3), 321–323. https://doi.org/10.1080/10550490490460300
   PubMed Web of Science ®Google Scholar
• Schjerning, O., Pottegård, A., Damkier, P., Rosenzweig, M., & Nielsen, J. (2016). Use of pregabalin - A nationwide pharmacoepidemiological drug utilization study with focus on abuse potential. Pharmacopsychiatry, 49(4), 155–161. https://doi.org/10.1055/s-0042-101868
   PubMed Web of Science ®Google Scholar
• Schwan, S., Sundström, A., Stjernberg, E., Hallberg, E., & Hallberg, P. (2010). A signal for an abuse liability for pregabalin-results from the Swedish spontaneous adverse drug reaction reporting system. European Journal of Clinical Pharmacology, 66(9), 947–953. https://doi.org/10.1007/s00228-010-0853-y
   PubMed Web of Science ®Google Scholar
• Smith, R. V., Lofwall, M. R., & Havens, J. R. (2015). Abuse and diversion of gabapentin among nonmedical prescription opioid users in Appalachian Kentucky. The American Journal of Psychiatry, 172(5), 487–488. https://doi.org/10.1176/appi.ajp.2014.14101272
   PubMed Web of Science ®Google Scholar
• Spence, D. (2013). Bad medicine: Gabapentin and pregabalin. BMJ (Clinical Research ed.), 347, f6747. https://doi.org/10.1136/bmj.f6747
   PubMedGoogle Scholar
• The Social Insurance Institution of Finland (KELA). (2020). Statistics on reimbursements for prescription medicines. Last modified: October 2019; Updated: October 2012. Retrieved November 8, 2020, from http://www.kela.fi/web/en/492
   Google Scholar
• WHO Collaborating Center for Drug Statistics Methodology. (2020). Retrieved November 8, 2020, from https://www.whocc.no/
   Google Scholar